ES2645262T3 - Métodos de uso de CD24 soluble para terapia de artritis reumatoide - Google Patents

Métodos de uso de CD24 soluble para terapia de artritis reumatoide Download PDF

Info

Publication number
ES2645262T3
ES2645262T3 ES11778000.7T ES11778000T ES2645262T3 ES 2645262 T3 ES2645262 T3 ES 2645262T3 ES 11778000 T ES11778000 T ES 11778000T ES 2645262 T3 ES2645262 T3 ES 2645262T3
Authority
ES
Spain
Prior art keywords
soluble
methods
rheumatoid arthritis
protein
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11778000.7T
Other languages
English (en)
Spanish (es)
Inventor
Xincheng Zheng
Wei Wu
Yang Liu
Pan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Application granted granted Critical
Publication of ES2645262T3 publication Critical patent/ES2645262T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11778000.7T 2010-04-28 2011-04-28 Métodos de uso de CD24 soluble para terapia de artritis reumatoide Active ES2645262T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
US329078P 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ES2645262T3 true ES2645262T3 (es) 2017-12-04

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11778000.7T Active ES2645262T3 (es) 2010-04-28 2011-04-28 Métodos de uso de CD24 soluble para terapia de artritis reumatoide
ES17183045T Active ES2826445T3 (es) 2010-04-28 2011-04-28 Uso médico de CD24 soluble

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17183045T Active ES2826445T3 (es) 2010-04-28 2011-04-28 Uso médico de CD24 soluble

Country Status (17)

Country Link
US (1) US8808697B2 (cg-RX-API-DMAC7.html)
EP (3) EP2563385B1 (cg-RX-API-DMAC7.html)
JP (5) JP5899206B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130086126A (cg-RX-API-DMAC7.html)
CN (2) CN105381451B (cg-RX-API-DMAC7.html)
AU (1) AU2011248540B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795823C (cg-RX-API-DMAC7.html)
DK (1) DK2563385T3 (cg-RX-API-DMAC7.html)
EA (2) EA027735B1 (cg-RX-API-DMAC7.html)
ES (2) ES2645262T3 (cg-RX-API-DMAC7.html)
IL (1) IL222739A0 (cg-RX-API-DMAC7.html)
NO (1) NO2563385T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ603196A (cg-RX-API-DMAC7.html)
PL (2) PL3260128T3 (cg-RX-API-DMAC7.html)
PT (2) PT3260128T (cg-RX-API-DMAC7.html)
SG (1) SG184907A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011139820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途
SG11201806338SA (en) * 2016-02-02 2018-08-30 Oncoimmune Inc Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
CN110461353A (zh) * 2017-03-07 2019-11-15 肿瘤免疫股份有限公司 可溶性cd24用于治疗系统性红斑狼疮的使用方法
KR20200034957A (ko) * 2017-05-15 2020-04-01 온코이뮨, 아이앤씨. 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
TWI835794B (zh) * 2018-05-14 2024-03-21 美商昂科Ｃ４公司 抗cd24組合物及其用途
EP3801773A4 (en) * 2018-06-04 2022-03-16 Oncoimmune, Inc. METHOD OF USE OF CD24 FOR PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
EP4017508A1 (en) * 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
HUP0303171A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ587776A (en) * 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
PL3260128T3 (pl) 2021-02-08
CA2795823A1 (en) 2011-11-10
DK2563385T3 (da) 2017-11-06
US8808697B2 (en) 2014-08-19
CN105381451B (zh) 2021-03-09
NZ603196A (en) 2014-07-25
EP2563385B1 (en) 2017-08-02
HK1222554A1 (zh) 2017-07-07
HK1176007A1 (zh) 2013-07-19
WO2011139820A1 (en) 2011-11-10
JP6888221B2 (ja) 2021-06-16
JP2015187162A (ja) 2015-10-29
CN105381451A (zh) 2016-03-09
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
ES2826445T3 (es) 2021-05-18
JP5899206B2 (ja) 2016-04-06
JP2017057216A (ja) 2017-03-23
PT2563385T (pt) 2017-11-10
EA036805B8 (ru) 2021-02-25
KR20130086126A (ko) 2013-07-31
PL2563385T3 (pl) 2018-04-30
IL222739A0 (en) 2012-12-31
JP2019151655A (ja) 2019-09-12
SG184907A1 (en) 2012-11-29
EP2563385A4 (en) 2013-10-02
CN102869369B (zh) 2016-05-18
EP3845238A1 (en) 2021-07-07
EA036805B1 (ru) 2020-12-23
EA201790538A3 (ru) 2017-11-30
CN102869369A (zh) 2013-01-09
JP2018127493A (ja) 2018-08-16
AU2011248540B2 (en) 2014-11-20
PT3260128T (pt) 2020-10-22
EA027735B1 (ru) 2017-08-31
EP2563385A1 (en) 2013-03-06
WO2011139820A8 (en) 2013-02-07
JP6062502B2 (ja) 2017-01-18
NO2563385T3 (cg-RX-API-DMAC7.html) 2017-12-30
JP6526872B2 (ja) 2019-06-05
EA201790538A2 (ru) 2017-07-31
EA201290961A1 (ru) 2013-04-30
JP2013527168A (ja) 2013-06-27
US20130136739A1 (en) 2013-05-30
EP3260128B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
ES2645262T3 (es) Métodos de uso de CD24 soluble para terapia de artritis reumatoide
JP7238000B2 (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
ES2626268T3 (es) Método de purificación de proteínas
ES2070919T5 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
ES2594408T3 (es) Método para purificar albúmina sérica humana a partir de grano de arroz transgénico
ES2769783T3 (es) Procedimiento de purificación de inmunoglobulina
ES2924109T3 (es) Composición que comprende una mezcla de isoformas de CD95-Fc
CN113382716A (zh) 通过将药物物质和药物产品过程整体化的生物制剂制造的连续制造过程
WO2011113601A1 (en) Method for obtaining biologically active recombinant human g-csf
ES2569343T3 (es) Procedimiento para extraer albúmina sérica humana a partir de grano de arroz transgénico
ES2224094T3 (es) Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica.
CN101497909B (zh) 制备抗a型肉毒毒素免疫球蛋白抗体的方法
ES2294696T3 (es) Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene.
CN102199198A (zh) 人呼吸道合胞病毒f蛋白的纯化方法
CN103111270B (zh) 一种乙型肝炎抗原蛋白的吸附材料及其制备方法
CN114195858B (zh) 多肽及其改造体和在制备抗炎杀菌药物中的应用
US20190002537A1 (en) Method for enriching a preparation of immunoglobulins with anti rsv immunoglobulins and preparation enriched in this way
ES2717683T3 (es) Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento contra el cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición
CN112375142A (zh) 静注新型冠状病毒人免疫球蛋白的制备方法
ES2717709T3 (es) Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento de cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición
JPH08505389A (ja) ヒトｒｓウイルスのｆｇ糖蛋白質の精製および再生方法
CN104109199B (zh) 一种聚乙二醇单修饰的人粒细胞集落刺激因子的制备方法及其产品
JPS6030292B2 (ja) 人顆粒球の分化増殖を促進する加熱処理ｈｇｉｇｐ及びｈｇｉｇｐの加熱処理法
WO2022101666A1 (en) Modular manufacturing unit, and components and methods for manufacturing infectious disease therapeutics using same
NO300895B1 (no) Fremgangsmåte for rensing av et humant rå-leukocyttinterferon